Kalaris Therapeutics (KLRS) Return on Capital Employed (2020 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Return on Capital Employed of 44.23% for Q1 2026, up 8112.0% year-over-year from 0.54% in Q1 2025, and up 12.08% quarter-over-quarter from 50.31% in Q4 2025.
Kalaris Therapeutics (KLRS) Return on Capital Employed (2020 - 2026) Analysis & Trends
Kalaris Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 44.23% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 8112.0% year-over-year to 44.23%; the TTM figure through Mar 2026 stood at 44.23% (up 8112.0% YoY), while the FY2025 annual figure was 85.1%, down 1498.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 44.23%, up from 50.31% in the prior quarter.
- The five-year high for Return on Capital Employed was 44.23% in Q1 2026, with the low at 130.49% in Q4 2024.
- The 5-year median for Return on Capital Employed is 76.55% (2023), against an average of 82.27%.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed plunged 6053 bps in 2022, then soared 8112 bps in 2026.
- Kalaris Therapeutics' Return on Capital Employed stood at 65.58% in 2022, then plunged by 59 bps to 104.56% in 2023, then decreased by 25 bps to 130.49% in 2024, then soared by 61 bps to 50.31% in 2025, then increased by 12 bps to 44.23% in 2026.
- Business Quant data shows KLRS's Return on Capital Employed at 44.23% in Q1 2026, 50.31% in Q4 2025, and 52.49% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | -49.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.79% |
| Mar 31, 2026 | -44.23% |
| Dec 31, 2025 | -50.31% |
| Sep 30, 2025 | -52.49% |
| Jun 30, 2025 | -74.84% |
| Mar 31, 2025 | -125.35% |
| Dec 31, 2024 | -130.49% |
| Sep 30, 2024 | -85.37% |
| Jun 30, 2024 | -85.88% |
| Mar 31, 2024 | -99.64% |
| Dec 31, 2023 | -104.56% |
| Sep 30, 2023 | -76.55% |
| Jun 30, 2023 | -74.71% |
| Mar 31, 2023 | -72.68% |
| Dec 31, 2022 | -65.58% |
| Sep 30, 2022 | -82.50% |
| Jun 30, 2022 | -97.51% |
| Mar 31, 2022 | -75.83% |
| Dec 31, 2021 | -64.40% |
| Sep 30, 2021 | -46.82% |